A Randomized, Double-Blind, Placebo/Active Controlled, Multiple Ascending Dose, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injections of YH35324 in Atopic Healthy Subjects or Subjects With Mild Allergic Diseases

YH35324-102

This study aims to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles following multiple subcutaneous injections of YH35324 in healthy subjects or subjects with mild allergic diseases, who have atopy.

2022-11-01

2023-12-31

2023-12-31

Recruiting

Early phase I

34

Inclusion Criteria: * Male or female adults aged ≥ 19 to ≤ 55 years * Serum total IgE level ≥ 30 IU/mL or 30 to 700 IU/mL or \>700IU/mL * Healthy subjects without any pathological symptoms or findings from medical examination, or subjects with a history of mild allergic diseases (allergic rhinitis, atopic dermatitis, food allergy, urticaria, or allergic asthma) Exclusion Criteria: * History of malignancy * Positive drug screen result * Aspartate transaminase (AST) or alanine transaminase (ALT) level \> 2 X the upper limit of normal * Estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula * Allergy immunotherapy initiated or changed within 6 months prior to randomization * History of participation in another clinical trial within 6 months prior to randomization

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'maskingDescription': 'As the YH35324 group and placebo group will be double-blinded, YH35324 and placebo will have the same appearance and packaging. Therefore, the double-blind will apply to the subjects, investigators, study coordinators, and study personnel including study pharmacists.\n\nThe active control omalizumab has a different appearance and packaging from YH35324 and placebo, and will be administered in an open-label manner.', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 34, 'type': 'ESTIMATED'}}

2023-04-21